Multiple Myeloma

The addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple myeloma who were able to meet their stem cell collection goals on first attempt.

The combination of daratumumab, ixazomib, and dexamethasone produced rapid and encouraging responses rates following lenalidomide–based therapy in patients with relapsed/refractory multiple myeloma, according to findings from the final analysis of the phase 2 DARIA trial.

The FDA has removed a partial clinical hold that had been placed on a phase 1 trial investigating the safety and efficacy of MT-0169 as a potential therapeutic option in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma.

Ciltacabtagene autoleucel significantly improved progression-free survival over standard-of-care pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.

The BCMA- and CD19-targeted CAR T-cell therapy GC012F continued to demonstrate a favorable safety profile with no new safety signals, and it elicited deep and durable responses in patients with relapsed/refractory multiple myeloma.

Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.

Talquetamab plus daratumumab displayed high response rates regardless of 0.4 mg/kg or 0.8 mg/kg dosing in combination with daratumumab in patients with heavily pretreated relapsed/refractory multiple myeloma, irrespective of prior treatment with CD38-directed therapy and T-cell redirection therapy.

Yael Cohen, MD, discusses primary efficacy findings from the phase 1/2 RedirecTT-1 trial, which is investigating the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

The BCMA/CD3 bispecific linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with relapsed/refractory multiple myeloma.

The CAR T-cell therapy PHE885 produced responses and high minimal residual disease negativity rates with no new safety signals in patients with relapsed/refractory multiple myeloma.

Teclistamab-cqyv in combination with talquetamab showcased early signs of activity with acceptable safety in patients with relapsed/refractory multiple myeloma, according to final results from the phase 1b RedirecTT-1 study.

Adam D. Cohen, MD, discusses unmet needs and areas for future investigation within the relapsed/refractory multiple myeloma treatment landscape.

Jeffery Zonder, MD, leader, multiple myeloma sub-committee, Barbara Ann Karmanos Cancer Institute, professor of medicine, Departments of Hematology and Oncology, Wayne State University School of Medicine, discusses ongoing research in multiple myeloma taking place at the Barbara Ann Karmanos Cancer Institute.

Natalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma.

Susan Bal, MD, discusses the data that supported the FDA approvals of ide-cel and cilta-cel, how the implementation of these agents has shifted how patients with later-line relapsed/refractory multiple myeloma are treated, and the challenges that still need to be addressed with CAR T-cell therapy.

Jeffery Zonder, MD, discusses the real-world use of ixazomib-based therapy for patients with relapsed/refractory multiple myeloma as seen in the INSURE study.

Susan Bal, MD, discusses the clinical implications for the use of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Michael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.

Andrew Kin, MD, discusses clinical implications of the FDA approval for teclistamab-cqyv in relapsed/refractory multiple myeloma.

Marilena Tauro, PhD, discusses next steps planned for the development of novel autophagy inhibitory strategies to combat chemotherapy resistance in relapsed/refractory multiple myeloma.

Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Meera Mohan, MD, MS, FACP, discusses the significance of CAR T-cell therapies and bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Susan Bal, MD, assistant professor, University of Alabama at Birmingham, discusses key efficacy and safety data from the phase 2 KarMMa trial in patients with relapsed/refractory multiple myeloma.

Attaya Suvannasankha, MD, discusses addressing the incidence of cytokine release syndrome in a first-in-human phase 1/2 trial for patients with relaped/refractory multiple myeloma.